株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

再灌流障害 - パイプライン製品の分析

Reperfusion Injury - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 245987
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
再灌流障害 - パイプライン製品の分析 Reperfusion Injury - Pipeline Review, H2 2014
出版日: 2014年11月30日 ページ情報: 英文 52 Pages
概要

再灌流障害は、血流不足による低酸素状態を一定時間経た後、血流が再開した際に起こる組織の損傷です。血液からの酸素供給不足により炎症や酸化的損傷が発生するもので、治療は抗酸化物質、抗白血球抗体、抗補体などによるものが挙げられます。

当レポートでは、再灌流障害に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

再灌流障害の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • NeuroVive Pharmaceutical AB
  • Scynexis, Inc.
  • Apeptico Forschung und Entwicklung GmbH
  • Stealth Peptides Inc.
  • Eustralis Pharmaceuticals Ltd
  • Nyken BV
  • Vasade Biosciences, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • cyclosporine
  • MTP-131
  • GNX-5086
  • bucillamine
  • Recombinant Protein to Inhibit CXCL for Cardiovascular and CNS Disorders
  • EUC-002
  • AP-301
  • NYK-1112
  • Type 5 Adenylyl Cyclase Inhibitors
  • Small Molecule for Reperfusion Injury
  • MitoSNO
  • PVIIA
  • RIIIK
  • Small Molecules to Inhibit Cyclophilin D for Ischemia Reperfusion Injury, Neurodegenerative Diseases, And Trauma
  • Synthetic Peptides to Activate Complement C3 for Immunology, Cardiovascular and CNS Disorders

パイプライン製品の最新動向

休止中のプロジェクト

開発中止になった製品

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5808IDB

Summary

Global Markets Direct's, 'Reperfusion Injury - Pipeline Review, H2 2014', provides an overview of the Reperfusion Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reperfusion Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Reperfusion Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Reperfusion Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Reperfusion Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Reperfusion Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Reperfusion Injury Overview
  • Therapeutics Development
    • Pipeline Products for Reperfusion Injury - Overview
    • Pipeline Products for Reperfusion Injury - Comparative Analysis
  • Reperfusion Injury - Therapeutics under Development by Companies
  • Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes
  • Reperfusion Injury - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Reperfusion Injury - Products under Development by Companies
  • Reperfusion Injury - Products under Investigation by Universities/Institutes
  • Reperfusion Injury - Companies Involved in Therapeutics Development
    • Apeptico Forschung und Entwicklung GmbH
    • NeuroVive Pharmaceutical AB
    • Nyken BV
    • Vasade Biosciences, Inc.
  • Reperfusion Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bucillamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GNX-5086 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MitoSNO - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NYK-1112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMC-6 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Opioid Delta for Reperfusion Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Reperfusion Injury - Recent Pipeline Updates
  • Reperfusion Injury - Dormant Projects
  • Reperfusion Injury - Discontinued Products
  • Reperfusion Injury - Product Development Milestones
    • Featured News & Press Releases
      • Feb 17, 2014: NeuroVive Treats Final Patient in European Phase III Trial on CicloMulsion
      • Aug 27, 2013: Congenia Announces Enrollment of First Healthy Volunteer in Phase 1
      • Jun 12, 2013: NeuroVive's Asian Subsidiary Receives First Milestone Payment From Sihuan Pharma
      • May 29, 2013: NeuroVive Provides Update On Ongoing Phase III Study Of CicloMulsion For Treatment Of Reperfusion Injury
      • May 27, 2013: New Chemical Compound Could Protect From Post-Heart Attack Tissue Damage, Researchers Report
      • Dec 03, 2012: NeuroVive Pharma Announces Publication Of Phase I Clinical Trial Of CicloMulsion In Clinical Drug Investigation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Reperfusion Injury, H2 2014
  • Number of Products under Development for Reperfusion Injury - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Reperfusion Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2014
  • Reperfusion Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2014
  • Reperfusion Injury - Pipeline by Nyken BV, H2 2014
  • Reperfusion Injury - Pipeline by Vasade Biosciences, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Reperfusion Injury Therapeutics - Recent Pipeline Updates, H2 2014
  • Reperfusion Injury - Dormant Projects, H2 2014
  • Reperfusion Injury - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Reperfusion Injury, H2 2014
  • Number of Products under Development for Reperfusion Injury - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top